Admune Therapeutics
Novartis acquires Admune Therapeutics
October 21, 2015Research and Development Admune Therapeutics, Cancer, Novartis, Palobiofarma, immunotherapy
Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …
Latest content
October 28, 2026
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
